Cellectar To Present Interim Phase 1b Data On Iopofosine In Pediatric Brain Cancer At AACR Conference

Author: Benzinga Newsdesk | August 27, 2025 08:09am

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for oral presentation followed by a 55-minute panel discussion with other experts in this area at the American Association for Cancer Research (AACR) Special Conference on Pediatric Cancer taking place September 25-28 in Boston, Massachusetts. The oral presentation will highlight interim data from the Phase 1b dose and regimen optimization study of iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG).

Posted In: CLRB